A federal consultative group voted Thursday to relax rules on seven peptides, including BPC-157 and TB-500. The vote was razor-thin. It is non-binding. The FDA has given no indication on whether it will act on the guidance. The move came after weeks of community hearings. Wellness backers pressed strongly for wider access. RFK Jr. was among them. Critics say these compounds have no solid safety track record or help for most uses. The call could change how the agency handles a part of the wellness market that is expanding rapidly. Market observers are watching to see if the FDA picks up the plan. A spokesperson offered no set date for a next move. Backers argue the change would open up access to substances users swear by. Skeptics warn that looser rules could invite misuse across a wide-open market. The committee vote only plants the seed for a shift, and the ultimate call rests with the federal agency.